While artificial intelligence (AI) has the potential to streamline trial design, enhance patient engagement, and accelerate timelines, it also introduces new ethical, regulatory, and operational challenges. This white paper breaks down what sponsors need to know to harness AI’s capabilities while maintaining compliance and participant protections.
Download your copy to explore:
- Key differences between machine learning, deep learning, and generative AI in research
- Use cases for AI across the clinical trial life cycle
- Ethical concerns including informed consent, data privacy, and algorithmic bias
- Best practices for transparency and participant communication
- FDA draft guidance on AI use and what it means for sponsors
- Actionable steps to ensure ethical oversight and regulatory readiness